Is Mobocertinib/Mobocertinib available in China?

Mobocertinib/Mobocertinib(Mobocertinib)atIt was approved for marketing by the US FDA in 2021 and will be launched in China in March 2023. Mobosetinib is indicated for adult patients with locally advanced or metastatic NSCLC who have epidermal growth factor receptor(EGFR)Exon20insertion mutation, as detected by an FDA-approved test, in patients whose disease has progressed during or after platinum-based chemotherapy.

Mobosetinib is an anti-tumor drug that works by interfering with the growth of cancer cells, which will eventually be destroyed. The retail price of Mobosetinib in domestic pharmacies is around 40mg/112 tablets/box>19,000/span> yuan per box. The Hong Kong clinical version has a retail price of 40mg30 tablets/span>7 more than a thousand per box in Hong Kong pharmacies. There are officially marketed generic drugs of Mobotinib overseas. Currently, they are produced in Bangladesh and Laos. The retail price of Mobotinib is 40mg 60 tablets3< /span>More than a thousand, the retail price of Lucius Pharmaceuticals in Laos40mg120 tablets4 is more than a thousand. At present, these two versions are officially on the market, have government approval, and the quality of the drugs is guaranteed. Patients can choose drug versions based on their financial situation. According to the trial, the median progression-free survival (PFS) for mobosetinib was 7.3 months (95% CIis5.5-9.2)Median overall survival(OS)is< span>24.0months(95%confidence interval is 14.6-28.8). If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.